We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Transforming Methylated Nucleic Acids into Prostate Tumor Biomarkers

By LabMedica International staff writers
Posted on 07 Apr 2014
High quality oligonucleoside reagents and detection kits are facilitating research on methylated DNA and its relation to the molecular mechanisms that drive development of prostate cancer.

In the March 31, 2014, online edition of the Integrated DNA Technologies (Coralville, IA, USA) newsletter DECODED, Dr. Antoinette Perry, senior research fellow at the Institute of Molecular Medicine (Dublin, Ireland), described how use of materials supplied by Integrated DNA Technologies (IDT) facilitated her research team's study of prostate cancer.

Research in Dr. Perry’s laboratory is directed at understanding how changes in DNA methylation of coding and non-coding RNA genes are involved in driving prostate carcinogenesis. The investigators exploit specific epigenetic changes for early, noninvasive detection of aggressive prostate cancer. In the process, they hope to develop predictive epigenetic biomarkers—focusing both on circulating free nucleic acids and exosomes—that can be quantified by simple, liquid biopsy. Ultimately, they hope to use these biomarkers to develop a noninvasive test that will distinguish high-risk from lower-risk prostate tumors.

Among the tools being used are IDT PrimeTime qPCR Assays and ZEN Double-Quenched Probes. These probes increase the accuracy and reliability of 5’ nuclease qPCR experiments. They contain an internal quencher only nine bases from the 5’ fluorescent label. This shortened distance, particularly when combined with the standard 3’ quencher, significantly decreases background fluorescence and increases sensitivity. Since, the initial background fluorescence signal is much lower than with traditional probes, it is much easier to detect subsequent changes and, therefore, functionally increases assay sensitivity.

Integrated DNA Technologies is one of the largest suppliers of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development.

Related Links:
Integrated DNA Technologies
Institute of Molecular Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
06 Apr 2014  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
06 Apr 2014  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
06 Apr 2014  |   BioResearch



PURITAN MEDICAL